electroCore (electroCore) Cash-to-Debt : 16.50 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is electroCore Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. electroCore's cash to debt ratio for the quarter that ended in Dec. 2023 was 16.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, electroCore could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for electroCore's Cash-to-Debt or its related term are showing as below:

ECOR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 20.92 Max: No Debt
Current: 16.5

During the past 8 years, electroCore's highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was 20.92.

ECOR's Cash-to-Debt is ranked better than
76.63% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs ECOR: 16.50

electroCore Cash-to-Debt Historical Data

The historical data trend for electroCore's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

electroCore Cash-to-Debt Chart

electroCore Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

11.92

8.00

45.58

25.34

16.50

electroCore Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															25.34	17.46	12.71	20.87	16.50

Competitive Comparison of electroCore's Cash-to-Debt

For the Medical Devices subindustry, electroCore's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

electroCore's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where electroCore's Cash-to-Debt falls into.

electroCore Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

electroCore's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	10.331	/	(0.089	+	0.537)
	=	16.50

electroCore's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	10.331	/	(0.089	+	0.537)
	=	16.50

electroCore (NAS:ECOR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

electroCore Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of electroCore's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

electroCore (electroCore) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866

Website

https://www.electrocore.com

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.

Executives

Daniel S Goldberger	director, officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Joseph P Errico	director, 10 percent owner, officer: See Remarks	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Thomas J. Errico	director, 10 percent owner	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
Trevor J Moody	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Julie Ann Goldstein	director	205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber	director	205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner	officer: Chief Financial Officer	1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L	director	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo	director	10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033